Virta Intervention in CommuniTies in COloRado (VICTOR-Pilot)

Not Applicable

Completed

• Conditions: Diabetes Mellitus, Type 2

• Registration Number: NCT04807218
• Lead Sponsor: Colorado Prevention Center

Brief Summary

The VICTOR study plans to include rural communities served by Colorado Heart Healthy Solutions (CHHS) program and find out whether participants will accept a referral to a comprehensive virtual lifestyle intervention, Virta Health. The Virta Health program induces nutritional ketosis to improve glucose control in individuals with type 2 diabetes. The study will inform the acceptability of the referral, the retention of participants in lifestyle intervention, and the durability of effects on glucose control after the lifestyle intervention has ended.

Detailed Description

In rural communities served by Colorado Heart Healthy Solutions (CHHS), referral to a comprehensive remotely-delivered (virtual) continuous remote care to induce nutritional ketosis combined with remote medication management will improve glycemic control in patients with type 2 diabetes as compared with standard care. The study intervention is the referral. Subjects are not mandated to receive Virta treatment and are welcome to continue in the study whether or not the referral is accepted. 2 rural communities served by CHHS have been chosen as recruitment sites. Study patients will be randomized at the site level.

Objectives

Primary: To assess glycemic control in patients with type 2 diabetes living in a rural community referred to a comprehensive remotely-delivered continuous remote care to induce nutritional ketosis combined with remote medication management (termed "continuous remote care") as compared with those living in a rural community offered standard care.

Secondary:

1. To assess the effects of referral to continuous remote care as compared with standard care on body weight and on body mass index

2. To assess the effects of referral to continuous remote care as compared with standard care on number and doses of anti-hyperglycemic medications

3. To determine the durability of a continuous remote care intervention when paired with ongoing community health worker support

Exploratory:

4. To assess the effects of referral to continuous remote care as compared with standard care on LDL-cholesterol, fasting glucose, and fasting triglyceride/HDL-cholesterol ratio

5. To assess patient-reported outcomes of continuous remote care as compared with standard care

6. To determine enrollment rate (offered vs accepted) in patients with type 2 diabetes living in rural communities referred to continuous remote care.

7. To determine active engagement (number, timing, and types of 2-way contacts) and retention in patients with type 2 diabetes living in rural communities referred to continuous remote care.

Study Timeline

• Study Start: 2021-03-02
• Study First Submitted: 2021-03-16
• Study First Submitted QC: 2021-03-17
• Study First Posted: 2021-03-19
• Primary Completion: 2024-08-30
• Study Completion: 2024-08-30
• Status Verified: 2025-02
• Last Update Submitted: 2025-03-07
• Last Update Posted: 2025-03-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

1. Able to provide electronic informed consent
2. Age 18 - 79 years old
3. Type 2 diabetes mellitus diagnosis by self-report and/or medical history
4. Taking 1 or more antihyperglycemic medications
5. Current HbA1c > 7.5%
6. Body mass index (BMI) 25 kg/m2 or greater
7. Capable of engaging in virtual care

Exclusion Criteria

1. Type 1 diabetes
2. Pregnant or planning pregnancy within the next 9 months
3. Lactating
4. Admission for diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar syndrome (HHS) within the last 12 months
5. Life expectancy <1 year
6. Postural orthostatic tachycardia syndrome (POTS) and/or recurrent syncope
7. Active severe psychiatric or medical condition(s) such as advanced renal (end-stage renal disease or CKD stage 4 or 5; eGFR <30 mL/min), cardiac (NYHA Class 4 heart failure), or hepatic dysfunction (Child-Pugh Class C)
8. Any condition which in the opinion of the investigator would make the study unsuitable for the subject including investigator opinion regarding inability to comply with Virta instructions

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Change in hemoglobin A1c (Percent)	3.5 months	Change from baseline hemoglobin A1c (Percent) among patients referred to continuous remote care (Group 1) versus standard care (Group 2)

Secondary Outcome Measures

Name	Time	Method
Change in BMI	Baseline versus 3.5 months, 3.5 months versus 7 months, baseline versus10 months	Among Group 1 versus Group 2 subjects, change in body mass index (kg/m2)
Change in hemoglobin A1c	3.5 months versus 7 months, baseline versus 10 months	Among Group 1 versus Group 2 subjects, difference in hemoglobin A1c
Change in number and/or doses of anti-hyperglycemic medications • doses of anti-hyperglycemic medications	Baseline versus 3.5 months, 3.5 months versus 7 months, baseline versus 10 months	Among Group 1 versus Group 2 subjects, difference in: * number of anti-hyperglycemic medications; * doses of anti-hyperglycemic medications

Trial Locations

Locations (3)

Northwest Colorado Health - Community Health Center & Prevention Services Craig; 🇺🇸 Craig, Colorado, United States

High Plains Community Health Center; 🇺🇸 Lamar, Colorado, United States

Chaffee County Public and Environmental Health; 🇺🇸 Salida, Colorado, United States